[1. Ostor AG. Natural history of cervical intraephitelial neoplasia: a critical review. Int J Gynecol Pathol. 1993; 12(2):186-9210.1097/00004347-199304000-00018]Search in Google Scholar
[2. Davey E, Barrat A, Irwing L, Chan SF, Macaskill P, Mannes P. Effect of study design and quality on unsatisfactory rates, cytology classifications and accuracy in liquid- based versus conventional cervical cytology: a systematic review. Lancet. 2006; 367(9505):122-3210.1016/S0140-6736(06)67961-0]Search in Google Scholar
[3. Confortini M, Bergeron C, Desai M, Negri G, Dalla Palma P, Montanari G, et al. Accuracy of liquid-based cytology: comparison of the results obtained within a randomized controlled trial (the New Technologies for Cervical Cancer Screening Study) and an external group of experts. Cancer Cytopathol. 2010 Aug 25;118(4):203-8.10.1002/cncy.20081]Search in Google Scholar
[4. Yim E-K, Park J-S. Biomarkers in Cervical Cancer. Biomark Insights. 2007 Feb 7;1:215-25.10.1177/117727190600100015]Search in Google Scholar
[5. von Knebel Doeberitz M. New markers for cervical dyspalsia to visualize the genomic chaos created by aberrant oncogenic papilomavirus infections. Eur J Cancer. 2002; 38(17):2229-4210.1016/S0959-8049(02)00462-8]Search in Google Scholar
[6. Koskimaa HM, Kurvinen K, Costa S, Syrjanen K, Szrjanen S. Molecular markers implicating early malignant events in cervical carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2010; 19(8)2003-12. Epub 2010 Jul 2010.1158/1055-9965.EPI-09-0781]Search in Google Scholar
[7. Malinowski D. Molecular diagnostic assays for cervical neoplasia: emerging markers for the detection of high-grade cervical disease. Biotechniques. 2005; Suppl: 17-2310.2144/05384SU03]Search in Google Scholar
[8. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000; 92(9):690-810.1093/jnci/92.9.690]Search in Google Scholar
[9. Naucler P, Ryd W, Törnberg S, Strand A, Wadell G, Hansson BG, et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br. J. Cancer. 2007 Jul 2;97(1):129-32.10.1038/sj.bjc.6603843]Search in Google Scholar
[10. Moscicki AB, Shiboski S, Broering J. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr. 1998; 132:277-8410.1016/S0022-3476(98)70445-7]Search in Google Scholar
[11. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV-16/18 vaccine. Int. J. Cancer. 2003 Oct 10;106(6):896-904.10.1002/ijc.11334]Search in Google Scholar
[12. Snidjers PJ, Steenbergen RD, Heideman DA, Meijer CJ. HPV mediated cervical carcinogenesis: conceps and clinical implications. J Pathol. 2006 Jan; 208(2):152-6410.1002/path.1866]Search in Google Scholar
[13. Wentzensen N, Vinokurova S, von Knebel Doeberitz M. Molecular markers of cervical squamous cell cancer precursor lesions. J Gynec Oncol. 2006; 11:30-40]Search in Google Scholar
[14. Duensing S, Munger K. The human papillomavirus type 16 E6 and E7 oncoproteins independently induce numerical and structural chromosome instability. Cancer Res. 2002;62(23):7075-82]Search in Google Scholar
[15. Melsheimer P, Vinokurova S, Wentzensen N, Bastert G, von Knebel Doeberitz M. DNA aneuploidy and integration of human papillomavirus type 16e7/e7 oncogenes in intraepithelial neoplasia and invasive squamous cell carcinoma of the cervix uteri. Clin Cancer Res. 2004; 10(9)3059-6310.1158/1078-0432.CCR-03-0565]Search in Google Scholar
[16. Koliopoulos G, Valasoulis G, Zilakou E. An update review on HPV testing methods for cervical neoplasia. Expert Opinion on Medical Diagnostics. 2009;3(2):123-31.10.1517/17530050802705680]Search in Google Scholar
[17. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst. 2011 Mar 2;103(5):368-83.10.1093/jnci/djq562]Search in Google Scholar
[18. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003; 362(9399):1871-6.10.1016/S0140-6736(03)14955-0]Search in Google Scholar
[19. Wetnzensen N, Vinokurova S, von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes in epithelial dysplasia and invasive cancer of the female genital tract. Cancer Res.2004; 64(11): 3878-8410.1158/0008-5472.CAN-04-000915172997]Search in Google Scholar
[20. Pett M, Coleman N.Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol.2007; 212(4):356-6710.1002/path.219217573670]Search in Google Scholar
[21. Goel MM, Mehrotra A, Singh U, Gupta HP, Misra JS. MIB-1 and PCNA immunostaining as a diagnostic adjunct to cervical Pap smear. Diagn. Cytopathol. 2005 Jul;33(1):15-9.10.1002/dc.2021815945082]Search in Google Scholar
[22. Pirog EC, Baergen RN, Soslow RA, Tam D, DeMattia AE, Chen YT. Diagnostic accuracy of cervical low grade squamous intraephitelial lesions is improved with MIB-1 immunostaining. Am J Surg Pathol. 2002; 26(1):70-510.1097/00000478-200201000-0000811756771]Search in Google Scholar
[23. Brown CA, Bogers J, Sahebali S, Depuydt CE, De Prins F, Malinowski DP.Role of Protein Biomarkers in the Detection of High-Grade Disease in Cervical Cancer Screening Programs.J Oncol. 2012; 2012: 289315, doi:10.1155/2012/28931510.1155/2012/289315331721422481919]Search in Google Scholar
[24. Golijow CD, Abba MC, Mouron SA, Gomez MA, Dulout FN. C-myc gene amplification detected in preinvasive intraephitelial neoplasia. Int J Gynecol Cancer. 2001; 11(6):462-510.1046/j.1525-1438.2001.01063.x11906549]Search in Google Scholar
[25. Klaes R, Friedrich T, Spitkovsy D, Ridder R., Rudy U, Petry G et al. Overexpression of p16ink4A as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer. 2001; 92:276-8410.1002/ijc.117411291057]Search in Google Scholar
[26. Sahebali S, Depuydt CE, Segers K, Moeneclay AJ, Vereecken AJ, Van Marck E, et al. P16INK4A as an adjunct marker inliquid-based cervical cytology. Int J Cancer. 2004; 108:871-610.1002/ijc.1158914712490]Search in Google Scholar
[27. Tringler B, Gup CJ, Singh M, Groshong S, Shroyer AL, Heinz DE et al. Evaluation of p16INK4A and pRB expression in cervical squamous and glandular neoplasia. Hum Pathol. 2004; 35:689-9610.1016/j.humpath.2004.02.01215188135]Search in Google Scholar
[28. Schorge JO, Lea JS, Elias KJ, Rajanbabu R, Coleman RL, Miller DS et al. P16INK4A as a molecular biomarker of cervical adenocarcinoma. Am J Obstet Gynecol. 2004; 190:66810.1016/j.ajog.2003.09.03815041997]Search in Google Scholar
[29. Passamonti B, Gustinucci D, Recchia P, Bulletti S, Carlani A, Cesarini E, et al. Expression of p16 in abnormal pap-tests as an indicator of CIN2+ lesions: a possible role in the low grade ASC/US and L/SIL (Ig) cytologic lesions for screening prevention of uterine cervical tumours. Pathologica. 2010; 102(1): 6-11]Search in Google Scholar
[30. Sung CO, Kim SR, Oh YL, Song SY. The use of p16 (INK4A) immunocytochemistry in "Atypical squamous cells which cannot exclude HSIL" compared with "Atypical squamous cells of undetermined significance" in liquidbased cervical smears. Diag.Cytopathol. 2010; 38(3):168-71]Search in Google Scholar
[31. Klaes R, Benner A, Freidrich T, Ridder R, Herrington S, Jenkins D. p16INK4a immunohistochemistry improves interobserver agreement in the diagnosis of cervical intraephitelial neoplasia. Am J Surg Pathol.2002; 26(11):1389-9910.1097/00000478-200211000-0000112409715]Search in Google Scholar
[32. Lee S, Kim H, Kim H, Kim C, Kim I.The Utility of p16INK4a and Ki-67 as a Conjunctive Tool in Uterine Cervical Lesions.Korean J Pathol. 2012 June; 46(3): 253-26010.4132/KoreanJPathol.2012.46.3.253347976223110011]Search in Google Scholar
[33. Ordi J, Garcia S, delPino M, Landolfi S, Alonso I, Quito L, et al.p16 INK4a immunostaining identifies occult CIN lesions in HPV-positive women. Int J Gynecol Pathol. 2009; 28(1):90-7.10.1097/PGP.0b013e31817e9ac519047902]Search in Google Scholar
[34. Carozzi F, Cecchini S, Confortini M, Becattini V, Cariaggi MP, Pontenani G. Role of p16 expression in identifying CIN2 or more severe lesions among HPV-positive patients reffered for colposcopy after abnormal cytology. Cancer. 2006 Apr 25; 108(2):119-2310.1002/cncr.2171316411180]Search in Google Scholar
[35. Tringler B, Gup CJ, Shroyer KR. Correlation between p16 and pRb expression in cervical squamous and glandular neoplasia. Human Pathol. 2004; 35:689-9610.1016/j.humpath.2004.02.01215188135]Search in Google Scholar
[36. Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Costa S et al; HPV-Pathogen ISS Study Group. Survivin as a marker of cervical intraepithelial neoplasia and high-risk human papillomavirus and a predictor of virus clearance and prognosis in cervical cancer. Am J Clin Pathol. 2005 Jul;124(1):113-2110.1309/L8BWF431WU9AC8FJ15923164]Search in Google Scholar
[37. Lu D, Qian J, Yin X, Xiao Q, Wang C, Zeng Y. Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci. 2012;69(4):143-6.10.1080/09674845.2012.12069142]Search in Google Scholar
[38. Wu SF, Zhang JW, Qian WY, Yang YB, Liu Y, Dong Y et al. Altered expression of survivin, Fas and FasL contributed to cervical cancer development and metastasis. Eur Rev Med Pharmacol Sci. 2012 Dec;16(15):2044-50.]Search in Google Scholar
[39. Ault KA, Allen HK, Phillips SL, Zimmerman MB, Klingelhitz AJ. Telomerase activity as a potential diagnostic marker for triage of abnormal Pap smears. J Low Genit Tract Dis. 2005; 9(2):93-910.1097/00128360-200504000-00005222306815870530]Search in Google Scholar
[40. Barbosa LC, da Silva ID, Correa JC, Ribalta JC. Survivin and telomerase expression in the uterine cervix of women with human papillomavirus-induced lesions. Int J Gynecol Cancer. 2011; 21(1):15-2110.1097/IGC.0b013e318203d42b21330827]Search in Google Scholar
[41. Tu Z, Zhang A, Wu R, Jiang J, Li Y, Wulan N et al. Genomic amplification of the human telomerase RNA gene for differential diagnosis of cervical disorders. Cancer Gent Cytogenet. 2009; 191(1):10-1610.1016/j.cancergencyto.2009.01.00419389503]Search in Google Scholar
[42. Porika M, Tippani R, Mohammad A, Bollam SR, Panuganti SD, Abbagani S. Evaluation of serum human telomerase reverse transcriptase as a novel marker for cervical cancer. Int J Biol Markers. 2011; 26(1):22-610.5301/JBM.2011.6352]Search in Google Scholar
[43. Samson SJ, Parker MR, Hessling JJ, Prpic DK, Hall L, Taylor AJ. Data comparison of three molecular markers (MCM7, p16 and integrin beta) for the detection of cervical dysplasia in SurePath cytology specimens.Acta Cytol.2004; 43:658]Search in Google Scholar
[44. Dilinuer A, Azar A, Colgan T, Nanji S. A Pilot Evaluation of a Novel Immunohistochemical Assay for Topoisomerase II-α and Minichromosome Maintenance Protein 2 Expression (ProEx C) in Cervical Adenocarcinoma In Situ, Adenocarcinoma, and Benign Glandular Mimics. Int J Gynecol Pathol.2009;28(2):114-910.1097/PGP.0b013e318189557319188825]Search in Google Scholar
[45. Sanati S, Huettner P, Ylagan LR. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol.2010; 29(1):79-9710.1097/PGP.0b013e3181ae81a019952938]Search in Google Scholar
[46. Baege AC, Disbrow GL, Schlegel R. IGFBP-3, a marker of cellular senescence, is overexpressed in human papillomavirus-immortalized cervical cells and enhances IGF-1 mitogenesis. J Virol.2004; 78:5720-710.1128/JVI.78.11.5720-5727.200441582815140969]Search in Google Scholar
[47. Guo M, Baruch AC, Silva EG, Jan Yj, Lin S, Sneige N, et al. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neo- plasia and cervical carcinoma. Am J Clin Pathol.2011 feb; 135(2):211-2010.1309/AJCP1LLX8QMDXHHO21228361]Search in Google Scholar
[48. Sanati S, Huettner P, Ylagan LR. Role of ProExC: a novel immunoperoxidase marker in the evaluation of dysplastic squamous and glandular lesions in cervical specimens. Int J Gynecol Pathol. 2010 Jan; 29(1):79-87.10.1097/PGP.0b013e3181ae81a019952938]Search in Google Scholar
[49. Heselmeyer-Haddad K, Sommerfeld K, Schrock E, duMS, Blegen H, Shah K, Steinbeck R. Gain of chromosome 3q defines the transition from severe dysplasia to invasive carcinoma of the uterine cervix. Proc Natl Acd Sci USA. 1996; 93(1):479-8410.1073/pnas.93.1.479402628552665]Search in Google Scholar
[50. Vazquez-Mena O, Medina-Martinez I, Juarez-Torres E, Barron V, Espinosa A, Villegas-Sepulveda N. Amplified genes may be overexpressed, unchanged, or down regulated in Cervical Cancer Cell Lines. PLoS One. 2012; 7(3): e3266710.1371/journal.pone.0032667329674522412903]Search in Google Scholar
[51. Mathevet P, Frappart L, Hittelman W. [Cervix dysplasias: study of Rb and p53 gene expression and correlation with mitotic activity]. Gynecol Obstet Fertil. 2000 Jan;28(1):44-50.]Search in Google Scholar
[52. Wentzensen N, Sherman NE, Schiffman M, Wang SS.Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol. 2009; 112(2):291-210.1016/j.ygyno.2008.10.012267371619054549]Search in Google Scholar
[53. Yang N, Nijhuis ER, Volders HH, Eijsink JJ, Lendvai A, Zhang B, et al. Gene promoter methylation patterns throughout the process of cervical carcinogenesis. Cell Oncol. 2010; 32(1-2): 131-43.10.1155/2010/306087]Search in Google Scholar
[54. Weaver EJ, Kovatich AJ, Bibbo M. Cyclin E expression and early cervical neoplasia in Thin Prep specimens. A feasability study. Acta Cytol. 2001; 25(7):884-91]Search in Google Scholar
[55. El-Ghobashy AA, Shaaba AM, Herod J, Innes J, Prime W, Herrington CS. Overexpression of cyclins A and B as markers of neoplastic glandular lesions of the cervix uteri. Gynecol Oncol. 2004; 92:628-3410.1016/j.ygyno.2003.11.01014766257]Search in Google Scholar
[56. Obermair A, Bancher-Todesca D, Bilgi S, Kaider A, Kohlberger P, Müllauer-Ertl S et al. Correlation of vascular endothelial growth factor expression and microvessel density in cervical intraepithelial neoplasia. J Natl Cancer Inst. 1997 Aug 20;89(16):1212-710.1093/jnci/89.16.12129274916]Search in Google Scholar
[57. Ozalp S, Yalcin OT, Oner U, Tanir HM, Acikalin M, Sarac I. Microvessel density as a prognostic factor in preinvasive and invasive cervical lesions. Eur J Gynaecol Oncol. 2003;24(5):425-8]Search in Google Scholar
[58. Branca M, Giorgi C, Ciotti M, Santini D, Di Bonito L, Costa S et al; HPV-Pathogen Istituto Superiore di Sanità Study Group. Down-regulated nucleoside diphosphate kinase nm23-H1 expression is unrelated to high-risk human papillomavirus but associated with progression of cervical intraepithelial neoplasia and unfavourable prognosis in cervical cancer. J Clin Pathol. 2006 Oct;59(10):1044-51.10.1136/jcp.2005.033142186174916537673]Search in Google Scholar